Group 1 - FDC Ltd has received ANDA approval from the US FDA for Pilocarpine Hydrochloride Ophthalmic Solution in concentrations of 1%, 2%, and 4% [1] - Apollo Hospitals Enterprise has acquired 8.5 million equity shares of Apollo Gleneagles PET-CT, making it a wholly-owned subsidiary [2] - Bajaj Healthcare has received a positive recommendation from the SEC to initiate Phase III clinical trials for Suvorexant tablets, becoming the first in India to receive regulatory approval for this insomnia treatment [3] Group 2 - AstraZeneca Pharma India has been granted permission to import Trastuzumab Deruxtecan for sale and distribution [4] - Torrent Pharmaceuticals has received demand notices exceeding ₹6.63 crore from the NPPA for alleged overcharging on five drugs from January 2016 to November 2018 [5] - The US FDA issued a Form-483 with four observations after inspecting Lupin's Pithampur Unit-2, classifying the inspection as 'Official Action Indicated' [6] Group 3 - The stalled open offer for a 26.1% stake in Fortis Healthcare by IHH Healthcare has been approved by SEBI, allowing IHH to proceed with the offer after seven years [7]